Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasm Metastasis 1Multiple Sclerosis, Chronic Progressive 1Multiple Sclerosis 1Multiple Myeloma 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Natalizumab × Clear all
NCT01416181 2017-09-11

ASCEND in SPMS

Biogen

Phase 3 Terminated
889 enrolled 31 charts

Multiple Sclerosis, Neoplasm Metastasis, Multiple Sclerosis, Chronic Progressive

NCT00675428 2014-09-19

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Biogen

Phase 1/2 Terminated
6 enrolled 6 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡